Last updated: May 26, 2026
Suppliers for YASMIN (drospirenone/ethinyl estradiol): Who manufactures the drug, API, and key components?
Quick answer: What supply chain pieces exist for YASMIN?
Yasmin is a branded oral contraceptive using drospirenone and ethinyl estradiol. The supply chain for this product typically breaks into: (1) finished-dose tablet manufacturing, (2) active pharmaceutical ingredient (API) manufacturing for drospirenone and ethinyl estradiol, and (3) excipient sourcing.
No verifiable supplier roster can be produced from the information provided.
What companies supply YASMIN tablets and who is the finished-dose manufacturer?
A credible supplier list for YASMIN requires company-level attribution from cGMP manufacturing filings and/or FDA labeling and regulatory inspection databases. Without a source document that identifies the manufacturer of record for YASMIN in the US market, a complete supplier map cannot be stated accurately.
Which firms manufacture drospirenone and ethinyl estradiol API used in YASMIN?
API suppliers are typically identifiable via FDA drug master files (DMFs), Orange Book manufacturing/labeler fields, or public regulatory records. The prompt provides no Orange Book listing, labeler/manufacturer field, DMF holders, or submission references tied to YASMIN, so the API supplier set cannot be enumerated without risking incorrect attribution.
How do excipients suppliers affect YASMIN supply continuity?
Tablet excipients (lactose, microcrystalline cellulose, starch derivatives, magnesium stearate, film-coat components, and others) are often sourced from multiple approved vendors across global supply chains. A supplier-grade excipient list for YASMIN depends on the formulation and the approved manufacturing process described in regulatory submissions or CMC sections, which are not provided.
What does the Orange Book show for YASMIN’s labeler/manufacturer of record?
Orange Book entries for each strength and dosage form can include a “labeler” and sometimes a manufacturing site attribution pathway. The prompt provides no specific YASMIN product entry, strength (for example 3 mg/0.03 mg), NDC, or Orange Book record to extract the labeler field and tied manufacturing information.
Which DMFs or CMC submissions typically identify YASMIN’s API and formulation suppliers?
For combination oral contraceptives, drospirenone and ethinyl estradiol may each be supported by separate DMFs and downstream CMC packages. Identifying the DMF holders and downstream applicants requires the FDA submission linkage, which is not available in the prompt.
How can supplier diversification reduce YASMIN launch and shortage risk?
Supplier diversification analysis requires at least one of: (a) the known manufacturer of record and (b) independent evidence of alternative sites in FDA records or quality agreements. Without those, any supplier diversification conclusions would be speculative.
Key Takeaways
- YASMIN’s supply chain includes finished-dose tablet manufacturing, drospirenone and ethinyl estradiol API manufacturing, and excipient sourcing.
- A precise supplier list requires product-specific regulatory identifiers (Orange Book entry, labeler/manufacturer fields, NDC, DMF holders, and/or FDA CMC attribution).
- The provided input does not contain the source data needed to name suppliers without error.
FAQs
- Where can I find the finished-dose manufacturer of YASMIN tablets in FDA records?
- Which Orange Book fields most directly identify the drug labeler for YASMIN?
- How are drospirenone and ethinyl estradiol DMF holders typically linked to branded products?
- What manufacturing-site information can be inferred from FDA inspection and labeling data for YASMIN?
- How do generics of drospirenone/ethinyl estradiol typically reveal API and excipient sourcing patterns?
References
- U.S. Food and Drug Administration (FDA). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- FDA. Drug Master Files (DMF) database and DMF guidance documents.
